3.03
0.11 (3.60%)
| 前收盘价格 | 2.92 |
| 收盘价格 | 2.99 |
| 成交量 | 130,427 |
| 平均成交量 (3个月) | 1,270,601 |
| 市值 | 327,744,352 |
| 价格/销量 (P/S) | 19.85 |
| 股市价格/股市净资产 (P/B) | 2.44 |
| 52周波幅 | |
| 利润日期 | 6 Nov 2025 |
| 营业利益率 (TTM) | -1,222.27% |
| 稀释每股收益 (EPS TTM) | -1.59 |
| 季度收入增长率 (YOY) | -39.30% |
| 总债务/股东权益 (D/E MRQ) | 1.72% |
| 流动比率 (MRQ) | 5.06 |
| 营业现金流 (OCF TTM) | -12.32 M |
| 杠杆自由现金流 (LFCF TTM) | -52.41 M |
| 资产报酬率 (ROA TTM) | -18.20% |
| 股东权益报酬率 (ROE TTM) | -91.03% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Aclaris Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.5 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.88 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.69% |
| 机构持股比例 | 88.24% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bml Capital Management, Llc | 30 Sep 2025 | 14,250,000 |
| Vivo Capital, Llc | 30 Sep 2025 | 8,888,888 |
| Rock Springs Capital Management Lp | 30 Sep 2025 | 4,609,309 |
| Decheng Capital Llc | 30 Sep 2025 | 4,041,736 |
| Palo Alto Investors Lp | 30 Sep 2025 | 1,566,840 |
| 52周波幅 | ||
| 中 | 16.00 (428.93%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Oct 2025 | 16.00 (428.93%) | 购买 | 2.01 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| DAVIS HUGH M. | - | - | 0 | 0 |
| 累积净数量 | 0 | |||
| 累积净值 ($) | 0 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| DAVIS HUGH M. | 职员 | 02 Dec 2025 | 执行期权 | 26,750 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合